

Dual-targeted therapy with trastuzumab and lapatinib in  
12/13 wild-type, HER2-positive metastatic colorectal cancer  
multicentre, open-label, phase 2 trial

Lancet Oncology, The

17, 738-746

DOI: [10.1016/s1470-2045\(16\)00150-9](https://doi.org/10.1016/s1470-2045(16)00150-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Role of targeted therapy in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 642.	0.8	80
2	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget, 2016, 7, 69060-69074.	0.8	29
3	Taking aim at the genomic diversity of gastrointestinal cancers: a changing landscape. Journal of Gastrointestinal Oncology, 2016, 7, 673-674.	0.6	0
4	Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. OncoTargets and Therapy, 2016, Volume 9, 7235-7245.	1.0	22
5	How the Lab is Changing Our View of Colorectal Cancer. Tumori, 2016, 102, 541-547.	0.6	15
7	Molecular pathology of cancer: how to communicate with disease. ESMO Open, 2016, 1, e000085.	2.0	20
9	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
10	Targeting HER2: precision oncology for colorectal cancer. Lancet Oncology, The, 2016, 17, 685-686.	5.1	5
11	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Emerging Drugs, 2016, 21, 267-282.	1.0	7
12	Targeted Therapy of Colorectal Cancer. Oncology Research and Treatment, 2016, 39, 796-802.	0.8	38
14	Implications and opportunities of precision medicine in rare malignancies. Expert Opinion on Orphan Drugs, 2016, 4, 953-960.	0.5	0
15	POLE mutations in colorectal cancer: a new biomarker?. The Lancet Gastroenterology and Hepatology, 2016, 1, 176-177.	3.7	9
16	Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. ESMO Open, 2016, 1, e000088.	2.0	85
17	In the literature: May 2016. ESMO Open, 2016, 1, e000071.	2.0	0
19	How Can Gastric Cancer Molecular Profiling Guide Future Therapies?. Trends in Molecular Medicine, 2016, 22, 534-544.	3.5	50
20	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical Cancer Research, 2017, 23, 3657-3666.	3.2	53
21	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	12.8	527
22	Antibodies for Treatment of Metastatic Colorectal Cancer. , 2017, , 217-244.		0

#	ARTICLE	IF	CITATIONS
23	Translating genomic profiling to gastrointestinal cancer treatment. <i>Future Oncology</i> , 2017, 13, 919-934.	1.1	7
24	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
25	Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. <i>Drugs and Aging</i> , 2017, 34, 173-189.	1.3	5
26	Molecular Stratification of Colorectal Cancer: Moving from the Laboratory to Clinical Practice. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 81-90.	1.0	0
27	HER2 as an Emerging Oncotarget for Colorectal Cancer Treatment After Failure of Anti-Epidermal Growth Factor Receptor Therapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, 247-251.	1.0	32
28	HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. <i>Clinical Colorectal Cancer</i> , 2017, 16, e147-e152.	1.0	32
29	Choosing wisely â€œ Preclinical test models in the era of precision medicine. <i>Cancer Treatment Reviews</i> , 2017, 55, 36-45.	3.4	37
30	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. <i>Annals of Oncology</i> , 2017, 28, 958-968.	0.6	107
31	Innovative Therapeutic Strategies Targeting Colorectal Cancer Stem Cells. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 91-100.	1.0	1
32	Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 102-113.	2.0	32
33	What We Know About Stage II and III Colon Cancer: Itâ€™s Still Not Enough. <i>Targeted Oncology</i> , 2017, 12, 265-275.	1.7	25
34	Treatment decisions in metastatic colorectal cancer â€œ Beyond first and second line combination therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 54-60.	3.4	99
35	Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2. <i>Scientific Reports</i> , 2017, 7, 1502.	1.6	20
36	Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. <i>Annals of Oncology</i> , 2017, 28, 1862-1868.	0.6	174
37	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. <i>Oncologist</i> , 2017, 22, 774-779.	1.9	16
38	Genetic and epigenetic markers in colorectal cancer screening: recent advances. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 665-685.	1.5	22
39	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 145-159.	0.9	1
40	Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer. <i>Human Pathology</i> , 2017, 66, 1-9.	1.1	31

#	ARTICLE	IF	CITATIONS
41	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	12.5	466
42	Current and future biomarkers in the treatment of colorectal cancer. <i>Acta Clinica Belgica</i> , 2017, 72, 103-115.	0.5	30
43	Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer. <i>JAMA Oncology</i> , 2017, 3, 481.	3.4	1
44	Copy number variations in <i>DCC</i> 18q and <i>ERBB2</i> 17q are associated with disease-free survival in microsatellite stable colon cancer. <i>International Journal of Cancer</i> , 2017, 140, 1653-1661.	2.3	10
45	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 79-92.	12.8	686
46	Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. <i>European Journal of Cancer</i> , 2017, 86, 305-317.	1.3	22
48	Molecular Profiling in Colon Cancer: Where Are We Now?. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 362-369.	1.0	0
49	Molecular Testing of Colorectal Cancer in the Modern Era. <i>Surgical Pathology Clinics</i> , 2017, 10, 1009-1020.	0.7	4
50	Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. <i>Annals of Oncology</i> , 2017, 28, 3009-3014.	0.6	72
52	Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1297-1308.	1.4	21
53	Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 2228-2239.	1.9	33
54	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer—A definite conclusion?. <i>Seminars in Oncology</i> , 2017, 44, 129-131.	0.8	3
55	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017, 2, e000147.	2.0	36
56	Precision Oncology: Present Status and Perspectives. <i>Current Clinical Pathology</i> , 2017, , 7-26.	0.0	0
57	Recent developments in the treatment of metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 551-564.	1.4	82
58	Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 333-342.	1.1	23
59	Evolution of anti-HER2 therapies for cancer treatment. <i>Cancer Treatment Reviews</i> , 2017, 59, 1-21.	3.4	73
60	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , 2017, 12, 525-533.	1.7	15

#	ARTICLE	IF	CITATIONS
61	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	3.2	148
62	Cancer predisposition syndromes: lessons for truly precision medicine. <i>Journal of Pathology</i> , 2017, 241, 226-235.	2.1	13
63	Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017, 28, 555-561.	0.6	43
64	Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance. <i>Seminars in Cell and Developmental Biology</i> , 2017, 64, 107-115.	2.3	71
65	Prolonged response of widely metastatic HER2-positive colon cancer to trastuzumab therapy. <i>Colorectal Cancer</i> , 2017, 6, 57-61.	0.8	2
66	The SHIVA01 trial: what have we learned?. <i>Pharmacogenomics</i> , 2017, 18, 831-834.	0.6	4
67	Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic <i>ERBB2</i> (HER2)-Amplified Duodenal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 983-988.	2.3	10
68	Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test. <i>Oncology Letters</i> , 2017, 14, 6045-6052.	0.8	6
70	Neural Biclustering in Gene Expression Analysis. , 2017, , .		1
71	Targeted therapies for gastric cancer: failures and hopes from clinical trials. <i>Oncotarget</i> , 2017, 8, 57654-57669.	0.8	99
72	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. <i>Oncotarget</i> , 2017, 8, 42198-42213.	0.8	49
73	Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. <i>JCO Precision Oncology</i> , 2017, 1, 1-6.	1.5	5
75	Development of Phosphorothioate DNA and DNA Thioaptamers. <i>Biomedicines</i> , 2017, 5, 41.	1.4	50
76	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1522.	1.8	23
77	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
78	FC $\gamma$ 3 Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. <i>Frontiers in Immunology</i> , 2017, 8, 457.	2.2	41
79	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	1.1	25
80	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. <i>Molecular Cancer</i> , 2017, 16, 116.	7.9	232

#	ARTICLE	IF	CITATIONS
82	Chemotherapies and future directions in metastatic colorectal cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 141-145.	0.3	0
83	Recent Advances in the Use of Molecular Biomarkers in Colorectal Cancer. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2017, 11, .	0.1	0
84	Molecular Testing for Gastrointestinal Cancer. Journal of Pathology and Translational Medicine, 2017, 51, 103-121.	0.4	54
85	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget, 2017, 8, 86356-86368.	0.8	147
86	Targeted therapies in breast cancer: New challenges to fight against resistance. World Journal of Clinical Oncology, 2017, 8, 120.	0.9	227
87	Genomics of peritoneal surface malignancies. Journal of Peritoneum (and Other Serosal Surfaces), 2017, , .	0.1	1
88	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 246-256.	1.8	20
89	Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment. Journal of Gastrointestinal Oncology, 2017, 8, 405-417.	0.6	17
90	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. Journal of Gastrointestinal Oncology, 2017, 8, 199-212.	0.6	26
91	Biologics in bowel cancer. Journal of Gastrointestinal Oncology, 2017, 8, 449-456.	0.6	4
92	Molecular Tests for the Choice of Cancer Therapy. Current Pharmaceutical Design, 2017, 23, 4794-4806.	0.9	10
93	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, e8-e15.	1.8	13
94	Molecular characterization of <i>ERBB2</i> -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Journal of Physical Education and Sports Management, 2018, 4, a002535.	0.5	16
95	First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients. Clinical Drug Investigation, 2018, 38, 553-562.	1.1	8
96	Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Current Treatment Options in Oncology, 2018, 19, 11.	1.3	3
97	MODULâ€”a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1197-1204.	1.2	30
98	Could New Drugs Offer Opportunities to Extend Resectability in Advanced Presentations?. , 2018, , 307-312.		0
99	What Chemotherapy to Recommend in Metastatic Patients?. , 2018, , 339-348.		0

#	ARTICLE	IF	CITATIONS
100	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 1-27.	0.1	1
101	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology, 2018, 29, 1108-1119.	0.6	177
102	Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients. Expert Review of Molecular Diagnostics, 2018, 18, 259-277.	1.5	4
103	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	2.0	29
104	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	13.7	572
105	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . Cancer, 2018, 124, 1358-1373.	2.0	151
106	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	3.2	59
107	Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer. Oncologist, 2018, 23, 474-477.	1.9	11
108	Dual-targeted nanomedicines for enhanced tumor treatment. Nano Today, 2018, 18, 65-85.	6.2	90
109	Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report. BMC Cancer, 2018, 18, 206.	1.1	9
110	High Expression of <i>PLOD1</i> Drives Tumorigenesis and Affects Clinical Outcome in Gastrointestinal Carcinoma. Genetic Testing and Molecular Biomarkers, 2018, 22, 366-373.	0.3	28
111	Molecular Landscape of <i>ERBB2/ERBB3</i> Mutated Colorectal Cancer. Journal of the National Cancer Institute, 2018, 110, 1409-1417.	3.0	53
112	Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer. Oncologist, 2018, 23, 1310-1318.	1.9	40
114	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	7.7	396
115	Clinical Trials and Progress in Metastatic Colon Cancer. Surgical Oncology Clinics of North America, 2018, 27, 349-365.	0.6	64
116	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. Methods in Molecular Biology, 2018, 1765, 281-297.	0.4	12
117	Biomarker-driven and molecular targeted therapies for colorectal cancers. Seminars in Oncology, 2018, 45, 124-132.	0.8	9
118	Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. JAMA Oncology, 2018, 4, 19.	3.4	16

#	ARTICLE	IF	CITATIONS
119	A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 807-820.	3.2	23
120	Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study. <i>Clinical and Translational Oncology</i> , 2018, 20, 785-793.	1.2	3
121	Molecular Markers and Mutational Analysis. , 2018, , 295-312.		1
122	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 231-238.	1.8	46
123	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 536-542.	0.8	362
124	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
126	Recent advances in understanding colorectal cancer. <i>F1000Research</i> , 2018, 7, 1528.	0.8	14
127	The Role of HER2 Testing in Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 184-191.	1.0	2
128	Novel Targets in Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 192-198.	1.0	1
129	Treatment of Rectal Cancer in Older Adults. <i>Current Oncology Reports</i> , 2018, 20, 102.	1.8	3
131	Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 113-131.	0.8	19
132	Targeted Therapy of Colorectal Cancer Subtypes. <i>Advances in Experimental Medicine and Biology</i> , 2018, , .	0.8	0
133	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 75-100.	0.8	7
134	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-11.	0.8	33
135	Inhibition of Wntless/GPR177 suppresses gastric tumorigenesis. <i>BMB Reports</i> , 2018, 51, 255-260.	1.1	11
136	Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. <i>Cancer Management and Research</i> , 2018, Volume 10, 5895-5908.	0.9	18
137	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
138	Cancers du cÅ1lon : prise en charge molÅ©culaire. <i>Revue Francophone Des Laboratoires</i> , 2018, 2018, 40-45.	0.0	1



#	ARTICLE	IF	CITATIONS
139	Case 32-2018: A 36-Year-Old Pregnant Woman with Newly Diagnosed Adenocarcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 1562-1570.	13.9	2
140	Association between Her2/neu status in colorectal carcinoma and clinicopathological features: a Retrospective study using whole tissue sections. <i>Polish Journal of Pathology</i> , 2018, 69, 143-149.	0.1	2
142	Membrane expression of thymidine kinase 1 and potential clinical relevance in lung, breast, and colorectal malignancies. <i>Cancer Cell International</i> , 2018, 18, 135.	1.8	26
143	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	1.6	93
144	Variability in HER2 expression between primary colorectal cancer and corresponding metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2275-2281.	1.2	20
145	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	7.7	187
146	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. <i>ESMO Open</i> , 2018, 3, e000353.	2.0	38
147	Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1780-1790.	0.9	14
148	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. <i>Oncologist</i> , 2018, 23, 1178-1187.	1.9	46
149	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 198-205.	1.0	57
150	TRKA expression and <i>NTRK1</i> gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , 2018, 71, 926-931.	1.0	12
151	Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. <i>Disease Markers</i> , 2018, 2018, 1-21.	0.6	38
152	Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. <i>Modern Pathology</i> , 2018, 31, 1882-1890.	2.9	49
153	Preclinical models for precision oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 239-246.	3.3	34
154	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2018, , .	1.8	5
155	Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 419-423.	2.9	12
156	Lapatinib. <i>Recent Results in Cancer Research</i> , 2018, 211, 19-44.	1.8	75
157	The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies. <i>Frontiers in Oncology</i> , 2018, 8, 263.	1.3	7

#	ARTICLE	IF	CITATIONS
158	HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 413-423.	1.4	12
159	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	7.7	129
160	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 31.	1.3	167
161	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. <i>British Journal of Cancer</i> , 2018, 119, 303-312.	2.9	29
162	Targeted therapy for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 991-1006.	1.1	44
163	Reinventing the randomized controlled trial in medical oncology: The registry-based trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 365-373.	0.7	30
164	Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma. <i>Journal of Translational Medicine</i> , 2018, 16, 183.	1.8	5
165	Promising New Agents for Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 29.	1.3	46
166	Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. <i>Future Oncology</i> , 2018, 14, 2437-2459.	1.1	7
168	Eastern Canadian Colorectal Cancer Consensus Conference 2017. <i>Current Oncology</i> , 2018, 25, 262-274.	0.9	4
169	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5815-5819.	3.2	25
170	Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1085-1092.	1.1	8
171	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. <i>Future Oncology</i> , 2018, 14, 2097-2102.	1.1	4
172	Molecular Variances Between Right- and Left-sided Colon Cancers. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 152-158.	1.0	5
173	HER2: An emerging target in colorectal cancer. <i>Current Problems in Cancer</i> , 2018, 42, 560-571.	1.0	67
174	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	1.8	4
175	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	0.6	32
176	Trastuzumab inhibits pituitary tumor cell growth modulating the TGFB/SMAD2/3 pathway. <i>Endocrine-Related Cancer</i> , 2018, 25, 837-852.	1.6	7

#	ARTICLE	IF	CITATIONS
177	HER2 positive rates are enriched amongst colorectal cancer brain metastases: a study amongst 1920 consecutive patients. <i>Annals of Oncology</i> , 2018, 29, 1598-1599.	0.6	12
178	Composite regulation of ERK activity dynamics underlying tumour-specific traits in the intestine. <i>Nature Communications</i> , 2018, 9, 2174.	5.8	42
179	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. <i>Precision Clinical Medicine</i> , 2018, 1, 29-48.	1.3	79
180	Quantifying and Processing Biomedical and Behavioral Signals. <i>Smart Innovation, Systems and Technologies</i> , 2019, , .	0.5	1
181	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019, 24, 319-326.	1.9	29
182	U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2043-2050.	1.9	51
183	<p>&lt;em>Comprehensive assessment of &lt;em>HER2&lt;/em> alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance&lt;/p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7867-7875.	0.9	7
184	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1510.	3.4	1
185	Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. <i>Cancer</i> , 2019, 125, 4139-4147.	2.0	299
186	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 83.	1.3	21
188	Molecular Approaches to Metastatic Colorectal Cancer: Better Diagnosis - Better Treatment?. <i>Visceral Medicine</i> , 2019, 35, 259-265.	0.5	5
189	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6243-6259.	3.2	42
190	Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. <i>Oncogene</i> , 2019, 38, 6109-6122.	2.6	20
191	Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis. <i>Theranostics</i> , 2019, 9, 3485-3500.	4.6	9
192	Importance of genetic screens in precision oncology. <i>ESMO Open</i> , 2019, 4, e000505.	2.0	10
193	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48
194	<p>&lt;em>The impact of panitumumab treatment on survival and quality of life in patients with &lt;em>RAS&lt;/em> wild-type metastatic colorectal cancer&lt;/p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5911-5924.	0.9	25
195	Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 6899-6908.	3.2	76

#	ARTICLE	IF	CITATIONS
196	Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?. CardioVascular and Interventional Radiology, 2019, 42, 1213-1220.	0.9	10
198	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. Expert Opinion on Biological Therapy, 2019, 19, 1247-1263.	1.4	29
199	Clinical Application of Next-Generation Sequencing as A Liquid Biopsy Technique in Advanced Colorectal Cancer: A Trick or A Treat?. Cancers, 2019, 11, 1573.	1.7	17
200	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. Journal of Gastrointestinal Oncology, 2019, 10, 831-840.	0.6	31
201	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precision Oncology, 2019, 3, 1-12.	1.5	20
202	Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Scientific Reports, 2019, 9, 16894.	1.6	8
203	Colorectal cancer. Lancet, The, 2019, 394, 1467-1480.	6.3	2,462
204	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. Cancer Control, 2019, 26, 107327481987054.	0.7	16
205	Precision medicine for metastatic colorectal cancer: an evolving era. Expert Review of Gastroenterology and Hepatology, 2019, 13, 919-931.	1.4	34
206	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. Cancer Treatment Reviews, 2019, 80, 101894.	3.4	37
207	Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer. BMC Cancer, 2019, 19, 880.	1.1	13
208	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. Cancers, 2019, 11, 1321.	1.7	34
209	Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports, 2019, 9, 13568.	1.6	14
210	Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. Journal of Clinical Oncology, 2019, 37, 3099-3110.	0.8	65
211	Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead. Journal of Clinical Oncology, 2019, 37, 3066-3068.	0.8	9
212	Self-circulating electrochemiluminescence chip for sensitive detection of circulating tumour nucleic acids in blood. Sensors and Actuators B: Chemical, 2019, 301, 127088.	4.0	5
213	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cellâ€™s Intrinsic Transcriptional MSI Traits. Cancer Research, 2019, 79, 5884-5896.	0.4	53
214	Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. Clinical Cancer Research, 2019, 25, 3210-3219.	3.2	35

#	ARTICLE	IF	CITATIONS
215	Current Status of Maintenance Systemic Therapies in Metastatic Colorectal Cancer: 2018 Update. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 28-35.	1.0	1
216	Treatment sequencing in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019, 109, 70-83.	1.3	215
217	Combination therapies with HSP90 inhibitors against colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 240-247.	3.3	81
218	Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma. <i>American Journal of Clinical Pathology</i> , 2019, 152, 97-108.	0.4	36
219	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
220	Immunohistochemistry-Enabled Precision Medicine. <i>Cancer Treatment and Research</i> , 2019, 178, 111-135.	0.2	5
221	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
222	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 236.	3.5	17
223	Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response. <i>Frontiers in Genetics</i> , 2019, 10, 470.	1.1	29
224	Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. <i>Journal of International Medical Research</i> , 2019, 47, 2768-2777.	0.4	7
225	Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	37
226	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019, 8, 3120-3130.	1.3	2
227	Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA. <i>Clinical Colorectal Cancer</i> , 2019, 18, 175-182.	1.0	11
228	[famâ€] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on <i>HER2</i> amplification. <i>International Journal of Cancer</i> , 2019, 145, 3414-3424.	2.3	62
229	Genetics of rectal cancer and novel therapies: primer for radiologists. <i>Abdominal Radiology</i> , 2019, 44, 3743-3750.	1.0	10
230	Isolated Metastases to Multiple Genital Organs: a Curious Case of Metachronous Spread of Carcinoma Colon. <i>Indian Journal of Surgical Oncology</i> , 2019, 10, 321-323.	0.3	0
231	CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1903.	1.8	15
232	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2019, 30, 1254-1264.	0.6	20

#	ARTICLE	IF	CITATIONS
233	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	30
234	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOC 80405 (Alliance). <i>Journal of Clinical Oncology</i> , 2019, 37, 1876-1885.	0.8	169
235	&lt;p&gt;Selecting treatment options in refractory metastatic colorectal cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2271-2278.	1.0	20
236	Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort. <i>Frontiers in Oncology</i> , 2019, 9, 212.	1.3	20
237	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	1.6	22
238	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. <i>Clinical Colorectal Cancer</i> , 2019, 18, 91-101.e3.	1.0	29
239	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362
240	Precision oncology giveth and precision oncology taketh away. <i>Lancet Oncology</i> , The, 2019, 20, 464-466.	5.1	3
241	HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 605.	3.4	32
242	Update on systemic therapy for colorectal cancer: biologics take sides. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 9-9.	1.5	22
243	Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2&acirc;Positive Salivary Duct Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 125-134.	0.8	157
244	Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 447-453.	1.9	17
245	The past, present, and future of HER2 (<i>ERBB2</i>) in cancer: Approaches to molecular testing and an evolving role in targeted therapy. <i>Cancer Cytopathology</i> , 2019, 127, 428-431.	1.4	1
246	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. <i>Journal of Surgical Oncology</i> , 2019, 119, 564-582.	0.8	55
247	The Developing Story of Predictive Biomarkers in Colorectal Cancer. <i>Journal of Personalized Medicine</i> , 2019, 9, 12.	1.1	111
248	Anti-tumor activity of antibody drug conjugate targeting aspartate-Î²-hydroxylase in pancreatic ductal adenocarcinoma. <i>Cancer Letters</i> , 2019, 449, 87-98.	3.2	14
249	Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3046-3053.	3.2	112
250	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. <i>Cancer Treatment Reviews</i> , 2019, 75, 1-11.	3.4	53

#	ARTICLE	IF	CITATIONS
251	First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-14.	0.7	4
252	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000813.	2.0	49
253	Report from the 20th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018. <i>Current Oncology</i> , 2019, 26, 773-784.	0.9	1
254	Enrichment of <i>HER2</i> Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. <i>Oncologist</i> , 2019, 24, 193-201.	1.9	16
255	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
256	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	1.8	34
257	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46
258	Colorectal Cancer Stratification in the Routine Clinical Pathway: A District General Hospital Experience. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, e54-e62.	0.6	7
259	Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes. <i>Scientific Reports</i> , 2019, 9, 18795.	1.6	5
260	Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	20
261	Human epidermal growth factor receptor 2-positive digestive tumors. <i>Current Opinion in Oncology</i> , 2019, 31, 354-361.	1.1	4
262	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. <i>Current Oncology</i> , 2019, 26, 24-32.	0.9	11
263	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	0.9	7
264	Predictive Biomarkers in Metastatic Colorectal Cancer: A Systematic Review. <i>JCO Precision Oncology</i> , 2019, 3, 1-17.	1.5	13
265	Supervised Gene Identification in Colorectal Cancer. <i>Smart Innovation, Systems and Technologies</i> , 2019, , 243-251.	0.5	0
266	Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019, 18, e140-e149.	1.0	5
267	A practical guide to biomarkers for the evaluation of colorectal cancer. <i>Modern Pathology</i> , 2019, 32, 1-15.	2.9	63
268	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 523-534.	0.9	3

#	ARTICLE	IF	CITATIONS
269	Resistance to EGFR Targeting Treatments in Colorectal Cancer. , 2019, , 257-269.		1
270	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. Clinical Colorectal Cancer, 2019, 18, e117-e129.	1.0	53
271	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clinical Cancer Research, 2019, 25, 2033-2041.	3.2	224
272	Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. JAMA Oncology, 2019, 5, 343.	3.4	280
273	Colorectal Cancer Biomarkers in the Era of Personalized Medicine. Journal of Personalized Medicine, 2019, 9, 3.	1.1	35
274	Predictive Biomarkers and Targeted Therapies in Colorectal Cancer. , 2019, , 423-430.		2
275	HER2-targeted therapy: an emerging strategy in advanced colorectal cancer. Expert Opinion on Investigational Drugs, 2019, 28, 29-38.	1.9	32
276	HER2-targeted therapies â€” a role beyond breast cancer. Nature Reviews Clinical Oncology, 2020, 17, 33-48.	12.5	569
277	Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer. Clinical and Translational Oncology, 2020, 22, 813-822.	1.2	24
278	Dynamic monitoring of HER2 amplification in circulating DNA of patients with metastatic colorectal cancer treated with cetuximab. Clinical and Translational Oncology, 2020, 22, 928-934.	1.2	9
279	Biomarker-guided therapy for colorectal cancer: strength in complexity. Nature Reviews Clinical Oncology, 2020, 17, 11-32.	12.5	195
280	Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 391-398.	1.4	17
281	Precision Treatment and Prevention of Colorectal Cancerâ€”Hope or Hype?. Gastroenterology, 2020, 158, 441-446.	0.6	12
282	Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Annals of Oncology, 2020, 31, 30-40.	0.6	124
283	International Harmonization of Provisional Diagnostic Criteria for <i>ERBB2</i> -Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. JCO Precision Oncology, 2020, 4, 6-19.	1.5	29
284	Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas. Lung Cancer, 2020, 140, 35-41.	0.9	22
285	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	3.2	66
286	Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2020, 82, 101935.	3.4	17



#	ARTICLE	IF	CITATIONS
287	Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC). <i>Diagnostics</i> , 2020, 10, 9.	1.3	24
288	Genetic Alterations of Metastatic Colorectal Cancer. <i>Biomedicines</i> , 2020, 8, 414.	1.4	27
289	lluminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
290	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. , 2020, , 1-27.		0
291	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
293	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
294	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1830.	1.7	2
295	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. <i>Gastroenterology Report</i> , 2020, 8, 179-191.	0.6	60
296	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , 2020, 31, 1135-1147.	0.6	58
297	Modern therapeutic approaches for the treatment of malignant liver tumours. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 755-772.	8.2	120
300	<p>Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer</p>. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 475-485.	1.5	7
301	Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment. <i>Cancers</i> , 2020, 12, 3481.	1.7	9
302	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 113-120.e1.	1.0	22
303	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3889.	1.0	35
304	A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy. <i>EBioMedicine</i> , 2020, 62, 103074.	2.7	32
305	Remarkable Response of EGFR- and HER2-Amplified Metastatic Colon Cancer to Pyrotinib After Failed Multiline Treatments: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 548867.	1.3	2
306	Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. <i>Scientific Reports</i> , 2020, 10, 19815.	1.6	7
307	Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. <i>Cancers</i> , 2020, 12, 2001.	1.7	2

#	ARTICLE	IF	CITATIONS
308	Towards the era of precision medicine in metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000685.	2.0	0
309	&lt;p&gt;Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects&lt;/p&gt;; <i>Cancer Management and Research</i> , 2020, Volume 12, 5819-5830.	0.9	8
310	Biomarkers in Colorectal Cancer: Current Research and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5311.	1.8	120
311	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093608.	1.4	37
312	Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm. <i>Frontiers in Oncology</i> , 2020, 10, 1369.	1.3	13
313	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , 2020, 91, 102112.	3.4	29
314	Adenosquamous carcinoma of the digestive system: a literature review. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1268-1276.	0.6	4
315	Radiomics predicts response of individual <scp>HER2</scp>-amplified colorectal cancer liver metastases in patients treated with <scp>HER2</scp>-targeted therapy. <i>International Journal of Cancer</i> , 2020, 147, 3215-3223.	2.3	27
316	Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Cancers</i> , 2020, 12, 2679.	1.7	44
317	Amphiregulin Expression Is a Predictive Biomarker for <i>EGFR</i> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. <i>Clinical Cancer Research</i> , 2020, 26, 6559-6567.	3.2	17
318	Somatic Testing and Germline Genetic Status: Implications for Cancer Treatment Decisions and Genetic Counseling. <i>Current Genetic Medicine Reports</i> , 2020, 8, 109-119.	1.9	0
320	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. <i>EBioMedicine</i> , 2020, 59, 102923.	2.7	22
321	Molecular Pathogenesis and Classification of Colorectal Carcinoma. <i>Current Colorectal Cancer Reports</i> , 2020, 16, 97-106.	1.0	12
322	Molecular Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 2350.	1.7	30
323	Patient-Derived Cancer Models. <i>Cancers</i> , 2020, 12, 3779.	1.7	9
324	Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1214.	1.7	26
325	Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2020, 22, 1976-1991.	1.2	13
326	Personalized Network Modeling of the Pan-Cancer Patient and Cell Line Interactome. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 399-411.	1.0	13

#	ARTICLE	IF	CITATIONS
327	Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies. <i>Cancers</i> , 2020, 12, 1168.	1.7	13
328	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 533.	1.3	17
329	Central Nervous System as Possible Site of Relapse in <i>ERBB2</i> -Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 927.	3.4	20
330	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308.	1.8	3
332	Integrating Academic and Community Practices in the Management of Colorectal Cancer: The City of Hope Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 1687.	1.0	5
333	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	1.5	7
334	Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study. <i>BMJ Open</i> , 2020, 10, e027665.	0.8	7
335	Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1566.	1.7	15
336	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. <i>Clinical Colorectal Cancer</i> , 2020, 19, 165-177.	1.0	15
337	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 251-270.	1.1	4
338	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
339	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159.	1.8	9
340	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
341	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
342	HER2 in Colorectal Carcinoma. <i>Surgical Pathology Clinics</i> , 2020, 13, 485-502.	0.7	24
343	Genomic Alterations of <i>NTRK</i> , <i>POLE</i> , <i>ERBB2</i> , and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1671-e1680.	1.9	17
344	Real-World Evidence in Oncology: Opportunities and Limitations. <i>Oncologist</i> , 2020, 25, e746-e752.	1.9	74
345	Inactivation of <i>NF1</i> Promotes Resistance to EGFR Inhibition in <i>KRAS/NRAS/BRAFV600</i> -Wild-Type Colorectal Cancer. <i>Molecular Cancer Research</i> , 2020, 18, 835-846.	1.5	22

#	ARTICLE	IF	CITATIONS
346	BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors. <i>BMC Cancer</i> , 2020, 20, 129.	1.1	9
347	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	1.8	7
348	Tumors of the Gastrointestinal System Including the Pancreas. , 2020, , 691-870.		0
349	Patient-derived xenografts (PDXs) as model systems for human cancer. <i>Current Opinion in Biotechnology</i> , 2020, 63, 151-156.	3.3	41
350	HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 65-72.	1.0	35
351	Patient-Derived Organoids: Promises, Hurdles and Potential Clinical Applications. <i>Clinical Oncology</i> , 2020, 32, 213-216.	0.6	3
352	Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 235-243.	1.9	36
353	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	3.2	62
354	Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 3-12.	0.7	1
355	Application of trastuzumab emtansine in HER2-positive and KRAS/BRAF-mutated colon cancer cells. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13255.	1.7	5
357	A systematic review of salvage therapies in refractory metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2020, 35, 783-794.	1.0	7
360	Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000634.	2.0	20
361	Liver transplantation for colorectal liver metastases: What do we need to know?. <i>International Journal of Surgery</i> , 2020, 82, 87-92.	1.1	24
362	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. <i>Clinical Cancer Research</i> , 2020, 26, 4107-4119.	3.2	68
363	Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 976-987.	1.9	127
364	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 688-701.	7.7	212
365	Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material. <i>BMC Cancer</i> , 2020, 20, 291.	1.1	20
366	Precision in cancer pharmacogenomics. <i>Pharmacogenomics</i> , 2020, 21, 311-316.	0.6	1

#	ARTICLE	IF	CITATIONS
367	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. <i>Cancer Treatment Reviews</i> , 2020, 86, 102023.	3.4	34
368	The unique immune microenvironment of liver metastases: Challenges and opportunities. <i>Seminars in Cancer Biology</i> , 2021, 71, 143-156.	4.3	35
369	Curcumin: A therapeutic strategy for colorectal cancer?. <i>Seminars in Cancer Biology</i> , 2021, 73, 321-330.	4.3	31
370	Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. <i>Clinical Cancer Research</i> , 2021, 27, 1612-1622.	3.2	16
371	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
372	Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 176-190.	157.7	101
374	Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report. <i>Clinical Colorectal Cancer</i> , 2021, 20, 96-99.	1.0	1
375	Controversies in the treatment of RAS wild-type metastatic colorectal cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 827-839.	1.2	3
376	Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 302-307.	0.7	31
377	New Molecular Targeted Therapy of Metastatic Colorectal Cancer. <i>The Ewha Medical Journal</i> , 2021, 44, 11-18.	0.1	1
378	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. <i>Advances in Cancer Research</i> , 2021, 151, 231-304.	1.9	8
379	ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. <i>Nature Biotechnology</i> , 2021, 39, 586-598.	9.4	81
380	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. <i>Gut</i> , 2022, 71, 119-128.	6.1	46
381	Protagonist of Immuno-Profilng, Immuno-Scoring, and Immunotherapy Towards Colitis-Associated Cancer. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 24-37.	0.1	0
382	Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. <i>Clinical Cancer Research</i> , 2021, 27, 1695-1705.	3.2	19
383	Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study. <i>Oncology</i> , 2021, 99, 665-672.	0.9	1
384	Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. <i>Biomedicines</i> , 2021, 9, 39.	1.4	18
385	Implications for the colorectal surgeon following the 100Â000 Genomes Project. <i>Colorectal Disease</i> , 2021, 23, 1049-1058.	0.7	4

#	ARTICLE	IF	CITATIONS
386	HER2 in metastatic colorectal cancer: a new to target to remember. <i>Biomarkers in Medicine</i> , 2021, 15, 135-138.	0.6	13
387	Diagnosis and Treatment of Metastatic Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 669.	3.8	941
388	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
389	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , 2021, 16, 309-324.	1.7	14
390	Recent Advances in Our Knowledge of mCRC Tumor Biology and Genetics: A Focus on Targeted Therapy Development. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2121-2130.	1.0	8
391	The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials. <i>Cancers</i> , 2021, 13, 1092.	1.7	40
392	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	2.7	6
393	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	3.4	14
394	HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors. <i>Cancers</i> , 2021, 13, 1047.	1.7	27
395	Clinical Utility of a Cell-Free DNA Assay in Patients With Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 589673.	1.3	10
396	High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer. <i>Experimental and Molecular Medicine</i> , 2021, 53, 446-456.	3.2	13
397	Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. <i>Scientific Reports</i> , 2021, 11, 7118.	1.6	5
398	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
399	Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 850-869.	0.5	9
400	A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX). <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 673-684.	1.2	5
401	Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy. <i>Histopathology</i> , 2021, 79, 227-237.	1.6	16
402	Routine Molecular Pathology Diagnostics in Precision Oncology. <i>Deutsches Arzteblatt International</i> , 2021, 118, .	0.6	2
403	HER2 Overexpression and Mismatch Repair Deficiency are Correlated with Malignancy in Colorectal Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 3443-3454.	0.9	0

#	ARTICLE	IF	CITATIONS
404	Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. <i>ESMO Open</i> , 2021, 6, 100040.	2.0	19
405	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. <i>Seminars in Cancer Biology</i> , 2022, 84, 199-213.	4.3	35
406	Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4774.	1.8	55
407	Rational Treatment of Metastatic Colorectal Cancer: A Reverse Tale of Men, Mice, and Culture Dishes. <i>Cancer Discovery</i> , 2021, 11, 1644-1660.	7.7	11
408	Precision oncology in metastatic colorectal cancer – from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 506-525.	12.5	113
409	Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2021, 22, 739-741.	5.1	1
410	The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021, 16, 517-527.	1.7	7
411	Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. <i>Oncologist</i> , 2021, 26, 640-646.	1.9	6
412	Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. <i>Cancer Discovery</i> , 2021, 11, 1886-1895.	7.7	12
413	Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 366-390.	0.8	4
414	Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5019.	1.8	8
415	Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma. <i>Oncologist</i> , 2021, 26, e1161-e1170.	1.9	8
416	Prevalence of HER2 overexpression and amplification in squamous cell carcinoma of the esophagus: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103339.	2.0	9
417	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. <i>Advances in Oncology</i> , 2021, 1, 297-310.	0.1	0
418	Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 178.	3.5	27
419	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3130.	1.7	13
420	FXVD6 Regulates Chemosensitivity by Mediating the Expression of Na <sup>+</sup> /K <sup>+</sup> -ATPase $\hat{1}$ and Affecting Cell Autophagy and Apoptosis in Colorectal Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-15.	0.9	11
421	HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 993-1002.	1.2	10

#	ARTICLE	IF	CITATIONS
422	TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs. <i>Pharmaceuticals</i> , 2021, 14, 632.	1.7	15
423	Genetic differences between lung metastases and liver metastases from left-sided microsatellite stable colorectal cancer: next generation sequencing and clinical implications. <i>Annals of Translational Medicine</i> , 2021, 9, 967-967.	0.7	7
424	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8
425	Genetic and biological hallmarks of colorectal cancer. <i>Genes and Development</i> , 2021, 35, 787-820.	2.7	159
426	Perspectives for circulating tumor DNA in clinical management of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1420-1430.	1.0	3
427	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 185.	3.5	20
428	Status quo and future prospects of artificial neural network from the perspective of gastroenterologists. <i>World Journal of Gastroenterology</i> , 2021, 27, 2681-2709.	1.4	11
429	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6813.	1.8	20
430	Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo. <i>Scientific Reports</i> , 2021, 11, 15125.	1.6	8
431	A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1358-1366.	1.2	2
432	Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7717.	1.8	7
433	Heterogeneous clinical and pathological landscapes of HER2 positive colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1097-1104.	1.1	2
434	Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 55-68.	1.0	3
435	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , 2021, 5, 1192-1199.	1.5	5
436	Novel Biomarker-Targeted Therapies for Metastatic Colorectal Cancer. <i>Digestive Disease Interventions</i> , 0, , .	0.3	0
437	Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection ( AIO KKR 0306; FIRE €). <i>International Journal of Cancer</i> , 2021, 149, 1935-1943.	2.3	3
438	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. <i>Cancer Treatment Reviews</i> , 2021, 98, 102218.	3.4	33
439	Landscape of Current Targeted Therapies for Advanced Colorectal Cancer. , 0, , .		0



#	ARTICLE	IF	CITATIONS
440	Pharmacogenomicâ€Guided Therapy in Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 616-625.	2.3	14
441	Macrophages, as a Promising Strategy to Targeted Treatment for Colorectal Cancer Metastasis in Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 685978.	2.2	15
443	Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line?. <i>Medical Alphabet</i> , 2021, , 30-35.	0.0	0
444	Molecular diagnostics and therapies for gastrointestinal tumors: a real-world experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2137-2144.	1.2	1
445	Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9369.	1.8	15
446	Pan-Cancer Molecular Biomarkers. <i>Surgical Pathology Clinics</i> , 2021, 14, 507-516.	0.7	4
447	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 155, 73-84.	1.3	13
448	Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy. <i>Cancers</i> , 2021, 13, 4803.	1.7	6
449	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. <i>Clinical Colorectal Cancer</i> , 2021, 20, 245-255.	1.0	2
450	The expressed mutational landscape of microsatellite stable colorectal cancers. <i>Genome Medicine</i> , 2021, 13, 142.	3.6	4
451	Improved Survival over Time After Resection of Colorectal Liver Metastases and Clinical Impact of Multigene Alteration Testing in Patients with Metastatic Colorectal Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 583-593.	0.9	17
452	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. <i>Cancers</i> , 2021, 13, 4506.	1.7	11
453	Clinicopathologic features and treatment advances in cancers with HER2 alterations. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188605.	3.3	11
455	Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project. <i>Cancer Research and Treatment</i> , 2021, 53, 123-130.	1.3	12
457	Biomarkers in the Management of Peritoneal Metastases. , 2020, , 251-279.		2
458	Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	6
459	Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 263-271.	0.9	16
461	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 161-173.	1.8	7

#	ARTICLE	IF	CITATIONS
462	Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status. <i>World Journal of Clinical Cases</i> , 2018, 6, 418-425.	0.3	7
463	Comparisons of metastatic patterns of colorectal cancer among patients by age group: a population-based study. <i>Aging</i> , 2018, 10, 4107-4119.	1.4	10
464	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. <i>Oncotarget</i> , 2017, 8, 67592-67604.	0.8	15
465	Identification and characterization of a novel <i>SCYL3-NTRK1</i> rearrangement in a colorectal cancer patient. <i>Oncotarget</i> , 2017, 8, 55353-55360.	0.8	33
466	Intratumoral heterogeneity and clonal evolution in blood malignancies and solid tumors. <i>Oncotarget</i> , 2017, 8, 66742-66746.	0.8	12
467	Copy number profiles of paired primary and metastatic colorectal cancers. <i>Oncotarget</i> , 2018, 9, 3394-3405.	0.8	14
468	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	0.8	12
469	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5
470	Colorectal cancer genomics and designing rational trials. <i>Annals of Translational Medicine</i> , 2018, 6, 159-159.	0.7	19
471	Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020, 32, 403-407.	0.7	10
472	Metastatic Colorectal Cancer: Prognostic and Predictive Factors. <i>Current Medicinal Chemistry</i> , 2020, 27, 2779-2791.	1.2	4
473	Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy. <i>Acta Biomedica</i> , 2018, 89, 102-106.	0.2	7
474	Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice. <i>Pathologica</i> , 2020, 112, 248-259.	1.3	35
475	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
476	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.	1.4	94
477	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1188-1196.	0.7	3
478	Precision medicine for gastrointestinal cancer: Recent progress and future perspective. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 12, 1-20.	0.8	31
479	Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 808-832.	0.8	59

#	ARTICLE	IF	CITATIONS
480	Response of human epidermal growth factor receptor 2-positive colorectal cancer to lapatinib monotherapy: A case report. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 1065-1072.	0.8	2
481	NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 806-815.	2.3	310
482	<i>HER2</i> and <i>BRAF</i> mutation in colorectal cancer patients: a retrospective study in Eastern China. <i>PeerJ</i> , 2020, 8, e8602.	0.9	12
483	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 117-129.	0.4	6
484	Molecular testing for colorectal cancer: Clinical applications. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1288-1301.	0.8	9
485	Genomic landscape of treatment refractory metastatic colorectal cancer. <i>Acta Oncol</i> , 2021, 60, 1621-1628.	0.8	2
486	Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 328.	3.5	62
487	Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2021, 17, 131.	1.0	0
488	Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. <i>World Journal of Clinical Oncology</i> , 2021, 12, 868-881.	0.9	8
489	Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. <i>Oncotarget</i> , 2017, 8, 105072-105080.	0.8	2
490	The Development of a New Molecular-Targeted Medicine for Metastatic Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2018, 71, 417-424.	0.1	0
491	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. , 2018, , 191-224.		0
492	Traitement du cancer colorectal mÃ©tastatique : ciblage molÃ©culaire. <i>Colon and Rectum</i> , 2018, 12, 178-183.	0.0	0
493	Unsupervised Gene Identification in Colorectal Cancer. <i>Smart Innovation, Systems and Technologies</i> , 2019, , 219-227.	0.5	4
494	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
495	GI Including GIST. , 2020, , 103-122.		0
496	Understanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain. <i>Smart Innovation, Systems and Technologies</i> , 2020, , 281-290.	0.5	0
499	Development of HER2-targeted Therapies for Gastrointestinal Cancer. <i>European Oncology and Haematology</i> , 2020, 16, 29.	0.0	0

#	ARTICLE	IF	CITATIONS
500	MODERN RADIOTHERAPY REGIMENS AND BIOMARKERS OF RADIORESISTANT RECTAL TUMOR CELLS. Siberian Journal of Oncology, 2020, 18, 105-113.	0.1	1
501	Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2357-2366.	0.5	2
502	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	21.5	41
503	Tailored Systemic Therapy for Colorectal Cancer Liver Metastases. International Journal of Molecular Sciences, 2021, 22, 11780.	1.8	7
504	ISH-based HER2 diagnostics. Der Pathologe, 2021, 42, 62-68.	0.7	3
505	Diagnostic, prognostic, predictive and therapeutic molecular biomarkers in CRC: Understanding the present and foreseeing the future. , 2022, , 207-230.		0
506	Molecularly targeted therapy in metastatic CRC. , 2022, , 357-364.		0
507	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1
508	Precision Medicine in Metastatic Colorectal Cancerâ€”Finding and Hitting the Right Targets. Oncology & Hematology Review, 2020, 16, 36.	0.2	0
511	The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2021, 22, 113.	1.3	9
512	Emerging Treatment Options for the Management of Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 949-952.	2.3	0
513	SystemÃ±c Chemotherapy in Colorectal Cancer. , 2021, , 693-705.		0
514	Colorectal Cancer: An Update on Treatment Options and Future Perspectives. Current Health Sciences Journal, 2019, 45, 134-141.	0.2	7
515	A Statistical Analysis of Risk Groups in Colorectal Cancer Patients. Current Health Sciences Journal, 2019, 45, 179-184.	0.2	0
516	Circulating tumor DNA in colorectal cancer: opportunities and challenges. American Journal of Translational Research (discontinued), 2020, 12, 1044-1055.	0.0	14
517	Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 670-674.	2.3	4
518	Options for the Treatment of Mucinous Ovarian Carcinoma. Current Treatment Options in Oncology, 2021, 22, 114.	1.3	9
519	New drugs for the treatment of metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2021, 13, 1551-1560.	0.8	3

#	ARTICLE	IF	CITATIONS
520	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	15.2	110
521	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. <i>Cancers</i> , 2021, 13, 5750.	1.7	4
522	Chinese consensus on prevention of colorectal neoplasia (2021, <sc>S</sc>hanghai). <i>Journal of Digestive Diseases</i> , 2022, 23, 58-90.	0.7	7
524	Emerging actionable targets to treat therapy-resistant colorectal cancers. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 36-63.	0.9	6
525	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. <i>Cancer Treatment Reviews</i> , 2022, 104, 102351.	3.4	34
526	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	1.4	23
527	Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 39.	0.3	1
528	Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data. <i>Journal of Personalized Medicine</i> , 2022, 12, 128.	1.1	6
529	ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100330.	1.5	3
530	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	3.4	21
531	Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome. <i>Current Medical Research and Opinion</i> , 2022, 38, 579-586.	0.9	0
532	Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 235-247.	1.9	3
533	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives. <i>Acta Oncologica</i> , 2022, 61, 523-530.	0.8	5
534	Clinicopathological and prognostic significance of HER2 status in surgically resected colorectal liver metastases. <i>Journal of Surgical Oncology</i> , 2022, 125, 991-1001.	0.8	3
536	Prognostic and Predictive Molecular Biomarkers in Advanced Colorectal Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
537	Neurological complications of GI cancers. , 2022, , 365-386.		0
538	Systemic treatment of localized colorectal cancer. , 2022, , 257-271.		0
539	CCDC12 promotes tumor development and invasion through the Snail pathway in colon adenocarcinoma. <i>Cell Death and Disease</i> , 2022, 13, 187.	2.7	2

#	ARTICLE	IF	CITATIONS
540	Molecular genetic testing in colon cancer: clinical aspects. <i>Al-Manah Kliničeskoj Mediciny</i> , 0, , .	0.2	0
541	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. <i>Cancers</i> , 2022, 14, 1197.	1.7	9
542	Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative. <i>Cancers</i> , 2022, 14, 1161.	1.7	15
543	The EurOPDX Data Portal: an open platform for patient-derived cancer xenograft data sharing and visualization. <i>BMC Genomics</i> , 2022, 23, 156.	1.2	10
544	Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. <i>Cancer Management and Research</i> , 2022, Volume 14, 821-842.	0.9	2
545	Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Colorectal Carcinoma: A Potential Area of Focus for Future Diagnostics. <i>Cureus</i> , 2022, 14, e22811.	0.2	1
546	Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	0
547	Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 437-441.	1.9	5
548	Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification. <i>Frontiers in Oncology</i> , 2022, 12, 856575.	1.3	13
549	Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2022, 8, 760.	3.4	35
550	Recent advances in nanoscale targeted therapy of HER2-positive breast cancer. <i>Journal of Drug Targeting</i> , 2022, 30, 687-708.	2.1	5
551	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1388.	1.7	22
553	Precision Oncology in Colorectal Cancers- Therapeutics and Beyond (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
554	Toward Targeted Therapies in Oesophageal Cancers: An Overview. <i>Cancers</i> , 2022, 14, 1522.	1.7	3
555	Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment. <i>BMC Cancer</i> , 2022, 22, 355.	1.1	2
556	HER2 targeted therapy in colorectal cancer: New horizons. <i>Cancer Treatment Reviews</i> , 2022, 105, 102363.	3.4	12
557	Current Updates on HER2-Directed Therapies in Metastatic Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2022, 18, 27.	1.0	0
558	Targeted Therapy for Colorectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 255-264.	0.6	19

#	ARTICLE	IF	CITATIONS
559	Dual targeting nanoparticles based on hyaluronic and folic acids as a promising delivery system of the encapsulated 4-Methylumbelliferone (4-MU) against invasiveness of lung cancer in vivo and in vitro. <i>International Journal of Biological Macromolecules</i> , 2022, 206, 467-480.	3.6	15
560	Development and Validation of a Targeted "Liquid"™ NGS Panel for Treatment Customization in Patients with Metastatic Colorectal Cancer. <i>Diagnostics</i> , 2021, 11, 2375.	1.3	3
572	The HER family as therapeutic targets in colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 174, 103681.	2.0	9
574	Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 116-119.	2.3	4
575	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 771-785.	0.3	1
576	Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population. <i>Frontiers in Oncology</i> , 2022, 12, 842787.	1.3	3
577	Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy. <i>Biomedicines</i> , 2022, 10, 1035.	1.4	5
578	Molecular genetic testing in colon cancer: clinical aspects. <i>AlĎmanah KliniĎeskoj Mediciny</i> , 2022, 50, 1-12.	0.2	1
579	Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 2223.	1.7	9
580	Antibody-drug conjugates: beyond current approvals and potential future strategies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 252-277.	0.5	11
581	Clinical management of metastatic colorectal cancer in the era of precision medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 372-401.	157.7	167
582	Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 2606.	1.0	5
583	FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint. <i>Journal of Personalized Medicine</i> , 2022, 12, 750.	1.1	13
584	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	7.7	48
585	Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth. <i>Cancer Medicine</i> , 2022, 11, 2824-2835.	1.3	13
588	Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	0
589	HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 219-232.	1.8	21
590	Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. <i>European Journal of Cancer</i> , 2022, 170, 64-72.	1.3	3

#	ARTICLE	IF	CITATIONS
591	Human Epidermal Growth Factor Receptor 2â€“Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues. JCO Oncology Practice, 2022, 18, 545-554.	1.4	8
592	Genomic and Transcriptomic Analysis of Microsatellite Instability-High Colorectal Cancer Patients with Targetable Alterations Identifies Clinical Implications for Immunotherapy. SSRN Electronic Journal, 0, , .	0.4	0
593	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. JAMA Network Open, 2022, 5, e2213588.	2.8	10
594	Review of the Role of HER2/neu in Colorectal Carcinomas. Cureus, 2022, , .	0.2	0
595	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. Targeted Oncology, 2022, 17, 271-281.	1.7	3
596	Pertuzumab Plus Trastuzumab for Treatment-Refractory <i>HER2</i>-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. JCO Clinical Cancer Informatics, 2022, , .	1.0	3
597	HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function. Scientific Reports, 2022, 12, .	1.6	3
600	Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers. PLoS ONE, 2022, 17, e0270139.	1.1	1
601	Application of histology-agnostic treatments in metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 1291-1303.	0.4	5
602	The current state of molecular profiling in gastrointestinal malignancies. Biology Direct, 2022, 17, .	1.9	5
603	Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers, 2022, 14, 2928.	1.7	34
604	Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer. Frontiers in Genetics, 0, 13, .	1.1	3
605	Mind the target: human epidermal growth factor receptor 2 in colorectal cancer. Current Opinion in Oncology, 0, Publish Ahead of Print, .	1.1	2
606	NK Cell-Based Immunotherapy in Colorectal Cancer. Vaccines, 2022, 10, 1033.	2.1	10
607	Radiomics-Guided Precision Medicine Approaches for Colorectal Cancer. Frontiers in Oncology, 0, 12, .	1.3	1
608	ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells. International Journal of Molecular Sciences, 2022, 23, 7127.	1.8	1
609	Challenges in the Management of Patients With HER2-Amplified Colorectal Cancer. JCO Oncology Practice, 0, , .	1.4	0
610	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 2022, 33, 750-768.	0.6	204



#	ARTICLE	IF	CITATIONS
611	Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, 347-353.	1.0	10
612	The Effective Role of Targeted Therapy in Advanced Colorectal Cancer. <i>Al Mustansiriyah Journal of Pharmaceutical Sciences</i> , 2022, 22, 20-27.	0.3	0
613	The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer. <i>Future Oncology</i> , 2022, 18, 2733-2744.	1.1	1
614	Efficacy and safety of HER2-targeted inhibitors for metastatic colorectal cancer with HER2-amplified: A meta-analysis. <i>Pharmacological Research</i> , 2022, 182, 106330.	3.1	3
615	Prognostic and predictive molecular biomarkers in advanced colorectal cancer. , 2022, 236, 108239.		17
616	Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?. <i>European Journal of Cancer</i> , 2022, 171, 25-42.	1.3	9
617	Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 176, 106259.	1.9	4
618	Use of molecular markers and other personalized factors in treatment decisions for metastatic colorectal cancer. , 2023, , 65-80.		0
619	Immunotherapy and targeted therapies for colorectal liver metastasis. , 2023, , 231-246.		0
620	New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. <i>Life</i> , 2022, 12, 1137.	1.1	2
621	Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene. <i>Cancers</i> , 2022, 14, 3718.	1.7	6
622	Biologics in rectal cancer. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-13.	1.4	0
623	ERBB2 (HER2) Alterations in Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 1064-1066.	1.2	4
624	Tailoring antiHer2 treatment strategies in breast cancer and beyond. <i>Current Problems in Cancer</i> , 2022, 46, 100892.	1.0	4
626	HER2 status is positively associated with vessel invasion of colorectal cancer: a retrospective large cohort study. <i>International Journal of Colorectal Disease</i> , 2022, 37, 2061-2067.	1.0	3
627	Role of dual anti-HER2 therapy before liver resection for rectal metastases. <i>Journal of Surgical Case Reports</i> , 2022, 2022, .	0.2	0
628	Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211117.	1.4	8
629	HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes. <i>Life</i> , 2022, 12, 1403.	1.1	8

#	ARTICLE	IF	CITATIONS
630	Towards precision oncology with patient-derived xenografts. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 719-732.	12.5	33
631	The Role of Biomarkers in the Management of Colorectal Liver Metastases. <i>Cancers</i> , 2022, 14, 4602.	1.7	5
632	Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	0
633	From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer. <i>International Journal of Cancer</i> , 2023, 152, 1304-1313.	2.3	4
634	Indications of Genomic Abnormalities for Molecular Targeted Therapy in Colorectal Cancer. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2022, 75, 449-452.	0.1	0
635	Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 5160.	1.7	7
636	Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR Study. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
637	Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. <i>Cancers</i> , 2022, 14, 4828.	1.7	11
638	Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy: A prospective cohort study. <i>World Journal of Gastrointestinal Oncology</i> , 0, 14, 2048-2060.	0.8	0
639	Overview of predictive and prognostic biomarkers and their importance in developing a clinical pharmacology treatment plan in colorectal cancer patients. <i>Expert Review of Clinical Pharmacology</i> , 0, , 1-10.	1.3	0
640	Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2023, 34, 10-32.	0.6	316
641	<i>Lactobacillus</i> Species as Probiotics: Isolation Sources and Health Benefits. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	1
642	Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. <i>Lancet Oncology</i> , The, 2022, 23, 1558-1570.	5.1	45
643	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
644	Dual targeted therapy with pyrotinib and trastuzumab for <i>HER2</i> -positive advanced colorectal cancer: A phase 2 trial. <i>Cancer Science</i> , 2023, 114, 1067-1074.	1.7	9
645	The predictive role of ERBB2 point mutations in metastatic colorectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2023, 112, 102488.	3.4	6
646	Targeted Therapy with Anti-EGFR and Anti-VEGF Therapy and Beyond. , 2022, , 293-299.		0
647	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292.		0

#	ARTICLE	IF	CITATIONS
648	The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. <i>Pathology</i> , 2023, 55, 8-18.	0.3	9
649	Novel 1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione derivatives for treating cancer and other disorders associated with KRAS activity. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 23, .	0.9	0
650	Biomarkers in the development of individualized treatment regimens for colorectal cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
651	Current Laboratory Testing Practices for Assessment of <i>ERBB2</i> /HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 1148-1157.	1.2	3
652	A 3D Perfusable Platform for In Vitro Culture of Patient Derived Xenografts. <i>Advanced Healthcare Materials</i> , 2023, 12, .	3.9	4
653	Role of Patient-Derived Models of Cancer in Translational Oncology. <i>Cancers</i> , 2023, 15, 139.	1.7	11
654	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7523.	1.0	1
655	Trastuzumab Combined with Irinotecan in Patients with HER2-Positive Metastatic Colorectal Cancer: A Phase II Single-Arm Study and Exploratory Biomarker Analysis. <i>Cancer Research and Treatment</i> , 2023, 55, 626-635.	1.3	5
656	The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. <i>Cancer Treatment Reviews</i> , 2023, 113, 102500.	3.4	15
657	Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2023, 38, .	1.0	0
658	Distinct Clinicopathological Features and Prognostic Values of High-, Low-, or Non-Expressing HER2 Status in Colorectal Cancer. <i>Cancers</i> , 2023, 15, 554.	1.7	1
659	Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
660	Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 755-767.	1.5	3
661	Molecular Basis of HER2-Targeted Therapy for HER2-Positive Colorectal Cancer. <i>Cancers</i> , 2023, 15, 183.	1.7	5
662	Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2351-2361.	3.2	2
663	New developments in targeted therapy for metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211485.	1.4	8
664	Therapeutic landscape and future direction of metastatic colorectal cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 306-322.	8.2	33
665	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. <i>World Journal of Gastroenterology</i> , 0, 29, 926-948.	1.4	4

#	ARTICLE	IF	CITATIONS
667	Exploiting bioactive natural products of marine origin: Evaluation of the meroterpenoid metachromin V as a novel potential therapeutic drug for colorectal cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114679.	2.5	2
668	KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103987.	2.0	3
669	Molecular Testing of Gastrointestinal Neoplasms. , 2024, , 395-405.		0
670	HER2 ~neu~™ promise for mCRC. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 8, 3-8.	0.0	0
671	Heterogeneous disease and intermittent treatment in metastatic colorectal cancer: A case report. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
672	CACA guidelines for holistic integrative management of rectal cancer. , 2023, 2, .		0
673	Metastatic colorectal cancer: mechanisms and emerging therapeutics. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 222-236.	4.0	30
674	A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2023, , .	1.0	0
675	Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 102-138.	0.5	14
676	Stage IV Colorectal Cancer Management and Treatment. <i>Journal of Clinical Medicine</i> , 2023, 12, 2072.	1.0	18
677	Advances and prospects of drug clinical research in colorectal cancer in 2022. , 2023, 2, 99-113.		1
678	Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. <i>World Journal of Gastroenterology</i> , 0, 29, 1395-1426.	1.4	8
679	Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. <i>Cancers</i> , 2023, 15, 1679.	1.7	6
680	Systemic treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1425-1444.	1.4	0
681	Systemic treatment for metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 0, 29, 1569-1588.	1.4	8
682	Frequency of Her2-low in colorectal cancer and its relations with the tumor microenvironment. <i>Pathology Research and Practice</i> , 2023, 244, 154417.	1.0	2
683	Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	3
684	Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics. <i>Pharmaceuticals</i> , 2023, 16, 614.	1.7	18

#	ARTICLE	IF	CITATIONS
685	Frequency of HER2 protein overexpression and HER2 gene amplification in endometrial clear cell carcinoma. Human Pathology, 2023, 137, 94-101.	1.1	2
688	A review on emerging targeted therapies for the management of metastatic colorectal cancers. , 2023, 40, .		6
720	Editorial: The impact of genetics on CRC therapy: from adaptive mutability to drug resistance. Frontiers in Oncology, 0, 13, .	1.3	0
727	Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds. , 2023, , 1-32.		0
743	Molecular Pathology of Colorectal Tumors. , 2023, , 133-154.		0
756	Current drug therapy for colorectal cancer. , 2024, , 115-148.		0